Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
Kura Oncology (Nasdaq: KURA) received a $30 million development milestone payment on Oct 24, 2025 after dosing the first patient in the frontline acute myeloid leukemia (AML) Phase 3 program for ziftomenib under its collaboration with Kyowa Kirin.
The payment followed the Sept 29, 2025 launch of KOMET-017 (NCT07007312), two global, randomized, double-blind, placebo-controlled Phase 3 trials testing once-daily oral menin inhibitor ziftomenib in newly diagnosed NPM1-mutated or KMT2A-rearranged AML across both intensive and non-intensive chemotherapy regimens.
Kura states KOMET-017 is the only menin inhibitor registrational program pursuing both chemotherapy settings.
Kura Oncology (Nasdaq: KURA) ha ricevuto un pagamento milestone di sviluppo pari a 30 milioni di dollari il 24 ottobre 2025 dopo aver sommministrato la prima dose al primo paziente nel programma di Fase 3 di frontline dell' AML (acute myeloid leukemia) per ziftomenib nell'ambito della sua collaborazione con Kyowa Kirin.
Il pagamento è avvenuto a seguito del lancio, il 29 settembre 2025, di KOMET-017 (NCT07007312), due studi globali, randomizzati, in doppio cieco e controllati con placebo di fase 3 che valutano ziftomenib, inibitore orale di menin assunto una volta al giorno, in AML recentemente diagnosticato con NPM1-mutato o KMT2A-rearranged, sia in regimi di chemioterapia intensivi che non intensivi.
Kura afferma che KOMET-017 è l'unico programma registracional di inibitori della menin che persegue entrambi i contesti di chemioterapia.
Kura Oncology (Nasdaq: KURA) recibió un pago por hito de desarrollo de 30 millones de dólares el 24 de octubre de 2025 después de administrar la dosis al primer paciente en el programa de Fase 3 de AML de primera línea para ziftomenib, dentro de su colaboración con Kyowa Kirin.
El pago se produjo tras el lanzamiento, el 29 de septiembre de 2025, de KOMET-017 (NCT07007312), dos ensayos globales, aleatorizados, doble ciego y controlados con placebo de fase 3 que evalúan ziftomenib, un inhibidor de menina oral de dosis diaria, en AML recién diagnosticado con NPM1 mutado o KMT2A rearranged, en regímenes de quimioterapia intensivos y no intensivos.
Kura afirma que KOMET-017 es el único programa registracional de inhibidores de menina que persigue ambos escenarios de quimioterapia.
Kura Oncology (나스닥: KURA)는 Kyowa Kirin과의 협력 하에 ziftomenib의 전방 AML 3상 프로그램에서 첫 환자에게 투약한 후 3천만 달러의 개발 이정표를 2025년 10월 24일 수령했습니다.
이 금액은 2025년 9월 29일 출시된 KOMET-017(NCT07007312)에 따른 것입니다. 이는 신규 진단된 NPM1 변이 또는 KMT2A 재배치 AML에서 하루 한 번 경구 복용하는 menin 억제제인 ziftomenib를 전력적이고 비전력적 화학요법 요법과 함께 비교하는 두 개의 전 세계적 무작위, 이중 맹검, 위약 대조의 3상 시험을 포함합니다.
Kura는 KOMET-017이 두 가지 화학요법 설정을 모두 추구하는 유일한 menin 억제제 등록 프로그램이라고 밝힙니다.
Kura Oncology (Nasdaq: KURA) a reçu un paiement d’objectif de développement de 30 millions de dollars le 24 octobre 2025 après avoir administré le premier patient dans le programme de phase 3 AML en première ligne pour le ziftomenib dans le cadre de sa collaboration avec Kyowa Kirin.
Le paiement est intervenu après le lancement, le 29 septembre 2025, de KOMET-017 (NCT07007312), deux essais mondiaux, randomisés, en double aveugle et contrôlés par placebo de phase 3 évaluant ziftomenib, un inhibiteur oral de menine pris une fois par jour, chez des AML nouvellement diagnostiqués mutés NPM1 ou réarrangés KMT2A, dans des régimes de chimiothérapie intensifs et non intensifs.
Kura indique que KOMET-017 est le seul programme d’inhibiteurs de la menine enregistrable poursuivant les deux configurations de chimiothérapie.
Kura Oncology (Nasdaq: KURA) erhielt am 24. Oktober 2025 eine Entwicklungsmeilensteinzahlung in Höhe von 30 Millionen Dollar nach der Verabreichung der ersten Dosis am ersten Patienten im Frontline-AML-Phase-3-Programm für Ziftomenib im Rahmen der Zusammenarbeit mit Kyowa Kirin.
Die Zahlung erfolgte nach dem Start von KOMET-017 (NCT07007312) am 29. September 2025, zwei globale, randomisierte, doppelblinde, placebokontrollierte Phase-3-Studien, die Ziftomenib, einen oralen Menin-Inhibitor, einmal täglich bei neu diagnostizierter NPM1-mutierter oder KMT2A-Rearrangement AML in sowohl intensiven als auch weniger intensiven Chemotherapie-Regimen testen.
Kura erklärt, dass KOMET-017 das einzige registrational-Programm für Menin-Inhibitoren ist, das beide Chemotherapie-Einstellungen verfolgt.
Kura Oncology (بورصة ناسداك: KURA) تلقّت دفعة أحدية للتطوير قيمتها 30 مليون دولار في 24 أكتوبر 2025 بعد إعطاء الجرعة الأولى للمريض الأول في برنامج المرحلة 3 من AML للمواجهة الأمامية لـ ziftomenib في إطار تعاونها مع Kyowa Kirin.
تأتي هذه الدفعة عقب إطلاق KOMET-017 (NCT07007312) في 29 سبتمبر 2025، وهما تجربتان عشوائيتان عالميتان مزدوجتا التعمية ومحكومتان بالدواء الوهمي من المرحلة 3 تختبران ziftomenib، مثبط منين فموي يؤخذ مرة واحدة يومياً في AML مُشخّصة حديثاً مع NPM1-mutated أو KMT2A-rearranged، عبر كل من نظم العلاج الكيميائي المكثف وغير المكثف.
وتؤكد Kura أن KOMET-017 هو البرنامج الوحيد المسجَّل لمثبّطات المينين الذي يسعى إلى كلا إعدادَي العلاج الكيميائي.
Kura Oncology (纳斯达克股票代码：KURA) 于 2025年10月24日 在 Kyowa Kirin 的合作下完成了前线急性髓系白血病（AML）3期计划中 ziftomenib 的首例给药后，获得了一个价值 3000万美元的开发里程碑支付。
在此之前，KOMET-017 (NCT07007312) 于 2025年9月29日 启动，这是两项全球性、随机、双盲、安慰剂对照的3期试验，评估每日一次口服的 menin 抑制剂 ziftomenib 在新诊断的 NPM1 突变 或 KMT2A 重排 AML中的应用，覆盖强化和非强化两种化疗方案。
Kura 表示 KOMET-017 是唯一同时追求两种化疗设置的 menin 抑制剂注册性项目。
- $30 million milestone payment received on Oct 24, 2025
- KOMET-017 launched on Sept 29, 2025
- Phase 3 registrational trials initiated (KOMET-017, NCT07007312)
- Program targets both intensive and non-intensive chemotherapy settings
- None.
- Milestone triggered by dosing of first patient in frontline AML Phase 3 clinical program-
SAN DIEGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced receipt of a
KOMET-017 (NCT07007312) comprises two independent, global, randomized double-blind, placebo-controlled Phase 3 trials to evaluate ziftomenib in combination with both intensive and non-intensive chemotherapy regimens in patients with newly diagnosed NPM1-mutated (NPM1-m) or KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML). Kura believes KOMET-017 is the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias and continues to pioneer advancements in menin inhibition for acute leukemias and solid tumors and in farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, statements regarding the therapeutic potential of ziftomenib and the KOMET-017 trial being the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, the risk that the collaboration with Kyowa Kirin is unsuccessful, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
Why did Kura Oncology (KURA) receive a $30 million payment on Oct 24, 2025?
What is KOMET-017 (NCT07007312) launched Sept 29, 2025 for KURA?
How does KOMET-017 evaluate ziftomenib across chemotherapy settings for KURA stockholders?
What drug is KURA developing with Kyowa Kirin in the Oct 24, 2025 announcement?
Does the Oct 24, 2025 milestone signal a change in trial status for KURA?
